Press Releases

ACR Congratulates FDA Commissioner Scott Gottlieb and Expresses Support for Biosimilar Review

ATLANTA - American College of Rheumatology President Sharad Lakhanpal, MBBS, MD, today issued the following statement congratulating Dr. Scott Gottlieb on his confirmation as Commissioner of the U.S. Food and Drug Administration.

“The ACR congratulates Dr. Scott Gottlieb on his confirmation as FDA Commissioner. As prescribing doctors, rheumatologists share Commissioner Gottlieb’s goal of optimizing FDA biosimilar and generic drug approvals to increase competition, lower costs, and improve our patients’ access to safe and proven therapies.

We are at a critical juncture in rheumatologic care, with the Centers for Disease Control and Prevention now reporting that 1 in 4 Americans live with doctor-diagnosed arthritis. Millions of these Americans cannot afford the biologic therapies they need to manage chronic pain, prevent joint and organ damage, and avoid long-term disability.

The FDA continues to play a critical role in lowering biologic drug costs as it works to bring safe, effective, and lower-cost biosimilar alternatives to the marketplace. Therefore, it is imperative that FDA have the funding and resources it needs to expedite biosimilar drug approvals, hire and retain qualified staff, issue guidance, and perform adequate post-market surveillance.

We look forward to working with Commissioner Gottlieb, Congressional leaders, and the Trump Administration to bolster the FDA’s important work on biosimilars to ensure more Americans can access safe, effective, and life-changing therapies.”

Jocelyn Givens
404-633-3777, ext. 810


The American College of Rheumatology (ACR) is the nation's leading advocacy organization for the rheumatology care community, representing more than 9,500 rheumatologists and rheumatology health professionals. As an ethically driven, professional membership organization committed to improving healthcare for Americans living with rheumatic diseases, the ACR advocates for high-quality, high-value policies and reforms that will ensure safe, effective, affordable, and accessible rheumatology care.

© 2022 American College of Rheumatology.  All rights reserved.  Website & Privacy Policies | Sitemap | Help | Contact Us